-2.99%
Today
Loading 1D prices…
Company profile
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.
Sector
Health Care
Industry
Surgical & Medical Instruments & Apparatus
Exchange
Nasdaq
Display currency
USD
Location
New York, NY, United States
Employees
82
Fiscal year end
1231
CIK
1799011
Session & valuation
Latest annual period
Deterministic peer set
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| KRMDKORU Medical Systems Inc. Common Stock (DE) | $145.1M | $41.1M | -6.41% | -$0.06 | +0.32% | Buy |
| NYXHNyxoah SA Ordinary Shares | $156.8M | — | — | -$2.36 | +2.67% | Hold |
| APYXApyx Medical Corporation Common Stock | $122.2M | $52.8M | -21.22% | -$0.27 | +0.35% | Buy |
| PDEXPro-Dex Inc. Common Stock | $201.2M | $77.5M | +17.62% | $4.12 | +4.96% | Hold |
| PYPDPolyPid Ltd. Ordinary Shares | $104.6M | $0.00 | — | $2.09 | -0.19% | Buy |